Other Transaction Agreement HR0011259E017
- Not listed
- Haima Therapeutics LLC was awarded a $1.6 million definitive cost-no-fee contract by the Department of the Army Medical Command to conduct applied research and development in response to the Congressionally Directed Medical Research Programs Fiscal Year 2019 Combat Readiness-Medical Research Program Rapid Development and Translational Research Award Broad Agency Announcement. Specifically, the prime contractor will perform work on a nanotechnology-enabled biosynthetic whole-blood surrogate for...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to JSL Innovations LLC, a small business, for the development of an Automated Hemorrhage Control Device. The contract has a ceiling value of $218,930.00 and a period of performance ending on March 25, 2022. The award was made on May 28, 2021 under a Broad Agency Announcement that sought proposals for SBIR and Small Business Technology Transfer (STTR) funding...
- <p>The U.S. Defense Advanced Research Projects Agency (DARPA) awarded a $483,009 firm-fixed-price contract to Cayuga Biotech Inc., a small disadvantaged business, to research accelerating coagulation in traumatic injuries using inorganic polyphosphate-coated silica nanoparticles. This contract, designated HR001116C0067, does not have a set-aside designation and has an ultimate completion date of April 13, 2017.</p>
- This is a $1,484,722.00 Cost Plus Fixed Fee contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Zymeron Corporation, a minority-owned small business located in Research Triangle Park, North Carolina. The contract was awarded under DARPA's Small Business Innovation Research (SBIR) program, Phase II, for the development of an "Automated Partial Occlusion for Truncal Hemorrhage Control" technology. This Phase II award builds upon earlier SBIR work and is...
- This federal contract award was issued by the Defense Health Agency (DHA) to Hybrid Plastics, Incorporated, a for-profit manufacturer, under the Small Business Innovation Research (SBIR) Program Phase II. The contract, valued at $999,997.59, is for the development of a "Hemostatic Agent" under the DHA PHASE II SBIR H2-0265 project. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, and the period of performance is from the award date of September 15, 2017...
- The Defense Health Agency has awarded a $249,980.33 firm fixed-price purchase order to FTL Labs Corp, a small business specializing in research and development based in Amherst, Massachusetts. This Small Business Innovation Research (SBIR) Program Phase I award is designated as a total small business set-aside and involves the development of the HemoSight Functional Platelet Evaluation Kit. The contract is expected to reach completion by January 2, 2026, with work performed at FTL Labs Corp's...
- This is a $225,000.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Technology Holding LLC, a small, for-profit limited liability company specializing in research and development services. The contract is part of DARPA's Small Business Innovation Research (SBIR) program and is for Phase I of an effort titled "AUTONOMOUS BIOMANUFACTORING AT REMOTE LOCATIONS". The contract has a total small business set-aside and supports the development of...
- The Defense Health Agency (DHA) awarded a $2.99 million Small Business Innovation Research (SBIR) Phase II direct contract to Perfusion Medical LLC on September 15, 2023, under Proposal H2D-0122. The contract, designated as a Total Small Business set aside, funds IND-enabling studies for PM-208, a novel pre-hospital anti-shock therapeutic. Work will be performed in Herndon, Virginia, with an ultimate completion date of July 14, 2026. This firm fixed-price definitive contract represents a...
- This is a definitive contract awarded by the Defense Health Agency (DHA) to Cellphire, Inc., a total small business, for the development of a Food and Drug Administration (FDA) licensed cryopreserved platelet (CPP) product for the U.S. Military. The contract has a ceiling value of $73,621,990.00 and a period of performance through February 28, 2027. The contract was originally solicited as a pre-solicitation notice by the U.S. Army Medical Materiel Development Activity (USAMMDA) in May 2019,...
- This federal contract award, valued at $1,499,722.00, was made by the Defense Advanced Research Projects Agency (DARPA) to Arete Associates, a small business contractor located in Northridge, California. The contract is part of DARPA's TRIAGE CHALLENGE (DTC) under the Signatures of Trauma for Algorithm-Assisted Clinical Assessment, Triage, and Observation (STACATO) program, which focuses on developing advanced sensing solutions for national security challenges. The contract has a completion date...
The Defense Advanced Research Projects Agency (DARPA) awarded a $2.0 million Other Transaction Agreement to Haima Therapeutics LLC, a Cleveland, Ohio-based woman-owned small business, on September 19, 2025. The contract, with an ultimate completion date of September 19, 2026, supports preclinical evaluation and development of Synthoplate, a field-deployable synthetic platelet surrogate designed for hemorrhage control applications. This award represents DARPA's investment in advanced medical technology that could enhance trauma care capabilities, particularly in military and emergency medical contexts where rapid hemorrhage control is critical. Haima Therapeutics LLC brings specialized expertise in nanotechnology-based hemostatic treatments and synthetic platelet therapeutic development to this engagement. The company's prior federal experience includes grant funding from the National Heart, Lung, and Blood Institute for developing Synthoplate technology to address bleeding complications in traumatic brain injury patients, as well as collaborative work with Case Western Reserve University on field-deployable dried platelet surrogates for combat-associated traumatic hemorrhage scenarios. The contract carries no set-aside designation and reflects DARPA's focus on advancing innovative medical countermeasures with potential applications across military medicine and civilian trauma response.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0m | 9/19/25 |